Agilent Technologies highlighted how lab automation and new instrumentation can scale antibody-drug conjugate (ADC) characterization for faster and more reproducible development. The focus is on operational throughput and repeatability across targeted biologic workflows—an area that becomes critical as ADC programs move from discovery into manufacturing-relevant characterization. The piece frames automation as a way to reduce variability in measurements and accelerate iteration cycles during linker-payload optimization and process development. For biopharma teams, the signal is clear: ADC modality complexity is driving increased reliance on automated analytical pipelines to keep CMC timelines aligned with clinical decision points.